"NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy"

In the ever-evolving landscape of neurological treatments, one company stands out for its innovative approach to managing epilepsy: NeuroOne Medical Technologies Corp. (NMTC). Today, NeuroOne CEO Dave Rosa joins the marketplace to discuss the latest advancements in epilepsy treatment, focusing on the company's groundbreaking technology that promises to revolutionize patient outcomes.

Epilepsy, a neurological disorder characterized by recurrent seizures, affects approximately 50 million people globally. Despite the availability of over 20 antiepileptic drugs (AEDs), about 36% of individuals with epilepsy experience uncontrolled seizures, significantly impacting their quality of life and mortality. Traditional treatments, including surgery, often fall short of providing effective management for all patients. This is where NeuroOne's innovative technology comes into play.

NeuroOne's Evo® Cortical Electrode portfolio consists of high-definition, minimally invasive thin film electrodes used for intracranial monitoring. These electrodes are implanted inside the skull to record brain activity, providing doctors with the tools to identify the exact location of seizure foci. Unlike traditional bulky electrodes, NeuroOne's electrodes are made with polyimide thin film, making them flexible, thin, and light. This reduces trauma to the brain and allows for less invasive implantation, monitoring brain activity for less than 30 days.



The Evo® sEEG Electrode technology enables the recording and monitoring of brain activity for less than 30 days, potentially reducing the need for multiple surgeries. This could lead to fewer hospital stays and adverse events, as well as lower procedural costs. For instance, the OneRF™ Ablation System, which has FDA 510(k) clearance, allows for temperature-controlled ablation of nervous tissue, potentially reducing the number of invasive procedures required.

The OneRF™ Ablation System, a stereoelectroencephalogram (sEEG)-guided tool, allows surgeons to record electrical activity and ablate nervous tissue under temperature-controlled environments. This system provides a new tool for neurosurgeons in the surgical management of epilepsy, with the ability to provide ablative therapy using already implanted depth electrodes used for diagnosing the epileptic focus as part of stereoEEG. This can lead to improved outcomes for patients with potential for fewer interventions and an improved therapeutic window.

The Epilepsy Treatment Drugs Market was valued at USD 8.3 billion in 2023 and is expected to grow at over 4.6% CAGR between 2024 and 2032. The key drivers propelling the expansion of the market involve the surge in recent approvals for new medications and the escalating prevalence of epilepsy globally. The introduction of NeuroOne's advanced technology could increase competition in the epilepsy treatment market. Other players may need to invest in R&D to develop similar or superior technologies to stay competitive.

In conclusion, NeuroOne's innovative technology offers a more precise and less invasive approach to diagnosing and treating epilepsy, which can lead to improved patient outcomes compared to traditional treatments. The company's recent FDA clearances and partnerships with Zimmer Biomet present potential financial opportunities for investors, but they also come with risks and challenges that should be carefully considered.